Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

This study tests a type of immune cell therapy called CAR-T cells, which are the patient's own immune cells engineered to target a protein called HER2 found on many solid tumors. The treatment is for people whose cancer has not responded to standard therapies. **You may be eligible if...** - You are between 18 and 70 years old with a HER2-positive solid tumor (such as stomach, ovarian, breast, bladder, colon, lung, or other cancer) - Your cancer has stopped responding to standard treatment - You have at least one measurable tumor on imaging - You are generally well enough to carry out daily activities - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active hepatitis B infection - You have certain serious infections or immune conditions - You have untreated brain metastases Talk to your doctor to see if this trial is right for you.